Perspectives for tailored chemoprevention and trea... [Crit Rev Oncol Hematol. 2010] - PubMed result

Crit Rev Oncol Hematol. 2010 Dec 13. [Epub ahead of print]
Perspectives for tailored chemoprevention and treatment of colorectal cancer in Lynch syndrome.

Heijink DM, de Vries EG, Koornstra JJ, Hospers GA, Hofstra RM, van Vugt MA, de Jong S, Kleibeuker JH.

Department of Medical Oncology, University Medical Center Groningen, University of Groningen, The Netherlands; Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, The Netherlands.

Abstract

Lynch syndrome (LS) is caused by a germline mutation in one of the mismatch repair (MMR) genes. The resulting loss of MMR gene function induces a strong mutator phenotype and predisposition to colorectal cancer (CRC). LS mutation carriers undergo regular colonoscopic surveillance and have extensive colonic resection in case of cancer because of the chance of metachronous tumors. Given the high risk and early onset of CRC, LS mutation carriers are good candidates for chemoprevention. Furthermore, evidence increases indicating that the response of MMR-deficient tumors to standard chemotherapy and radiotherapy differs from that of MMR-proficient tumors. Efforts should thus be directed at designing tailored strategies concerning both chemoprevention and medical cancer treatment for LS individuals. This review provides guidance for future studies in this field based on results from clinical and preclinical research.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

PMID: 21159521 [PubMed - as supplied by publisher]
Perspectives for tailored chemoprevention and trea... [Crit Rev Oncol Hematol. 2010] - PubMed result